Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors

NCT00633789 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00633789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00633789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
December 31, 2012
Enrollment
597 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer, gastric/esophageal adenocarcinoma, pancreatic cancer including ampulla of vater, soft tissue sarcoma, transitional cell carcinoma